Regeneron Covid-19 drug cuts risk of death in some patients

Good morning, folks. And how are you today? We are in fine spirits, thanks to a sunny sky and a delightful breeze that are enveloping the Pharmalot campus. Of course, there is little time to enjoy the moment since there is so much to be done. It is the middle of the week, after all. No doubt, you can relate. So time to get cracking. Let’s grab that cup of stimulation and attack the to-do list. Meanwhile, here are some items of interest. Hope you conquer the world today and keep us in mind if you hear anything interesting. …

A monoclonal antibody treatment for Covid-19 developed by Regeneron Pharmaceuticals (REGN) saved lives among hospitalized patients who had not mounted their own immune response, a finding that could dramatically change the way that doctors will use the therapy, STAT explains. The new data from a trial of nearly 10,000 patients mark the first time that a medicine that works by fighting the SARS-CoV-2 virus has been shown to reduce mortality.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED


Source link

DrAbout.Net

The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button